JOURNAL OF CONTROLLED RELEASE

Scope & Guideline

Shaping the evolution of controlled release methodologies.

Introduction

Welcome to your portal for understanding JOURNAL OF CONTROLLED RELEASE, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0168-3659
PublisherELSEVIER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1984 to 2024
AbbreviationJ CONTROL RELEASE / J. Control. Release
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The Journal of Controlled Release focuses on the development and application of advanced drug delivery systems and nanomedicines. Its core research areas encompass a wide array of methodologies aimed at optimizing the therapeutic efficacy and safety of drugs through controlled release mechanisms.
  1. Drug Delivery Systems:
    Research on various drug delivery systems including nanoparticles, liposomes, hydrogels, and microneedles designed to improve the bioavailability and efficacy of therapeutic agents.
  2. Nanomedicine:
    Exploration of nanotechnology applications in medicine, focusing on the design, synthesis, and evaluation of nanomaterials for targeted drug delivery and therapy.
  3. Therapeutic Formulations:
    Development of innovative formulations that enhance the delivery and release profiles of drugs, including responsive systems that react to specific biological stimuli.
  4. Biomaterials Engineering:
    Investigation of biocompatible materials for drug delivery systems, emphasizing the interaction between drugs and the biological environment to optimize therapeutic outcomes.
  5. Clinical Applications:
    Translation of laboratory findings to clinical settings, assessing the safety and efficacy of new drug delivery technologies in various therapeutic areas.
  6. Immunotherapy:
    Integration of drug delivery systems with immunotherapeutic strategies to enhance the immune response against cancer and other diseases.
The Journal of Controlled Release is witnessing exciting trends and emerging themes that reflect the evolving landscape of drug delivery research. These areas are gaining traction and are likely to shape the future of the field.
  1. Stimuli-Responsive Drug Delivery:
    Research on drug delivery systems that respond to specific stimuli (e.g., pH, temperature, or light) is increasing, enabling more precise control over drug release profiles.
  2. Extracellular Vesicles (EVs):
    The use of EVs as drug delivery vehicles is gaining prominence, leveraging their natural ability to facilitate cellular uptake and modulate immune responses.
  3. CRISPR and Gene Editing Technologies:
    The integration of CRISPR and other gene editing technologies into drug delivery systems is emerging as a powerful approach for targeted genetic therapies.
  4. Nanomaterials for Cancer Therapy:
    Innovative nanomaterials designed for cancer therapy, including those that enhance immunogenicity and target the tumor microenvironment, are rapidly advancing.
  5. Personalized Medicine Approaches:
    The shift towards personalized medicine is reflected in research aimed at tailoring drug delivery systems to individual patient needs, improving treatment outcomes.
  6. Combination Therapies:
    There is a growing trend in combining different therapeutic modalities (e.g., chemotherapy and immunotherapy) within a single delivery system to enhance therapeutic efficacy.

Declining or Waning

While the Journal of Controlled Release has maintained a strong focus on drug delivery and nanomedicine, certain areas have seen a decline in research output. These waning scopes may reflect shifting interests within the scientific community or advancements in alternative methodologies.
  1. Conventional Drug Delivery Methods:
    There is a noticeable decline in research focused on traditional drug delivery methods as the field shifts towards more innovative approaches like nanotechnology and personalized medicine.
  2. Non-targeted Drug Delivery:
    Research on non-targeted delivery systems is decreasing as there is a growing emphasis on targeted therapies that improve specificity and reduce side effects.
  3. Passive Release Mechanisms:
    Studies exploring passive release mechanisms are becoming less common, with a trend towards developing stimuli-responsive systems that offer more control over drug release.
  4. Single-Modal Therapies:
    The exploration of single-modal therapies is waning as there is a shift towards combination therapies that integrate multiple modalities for enhanced efficacy.
  5. In vitro Models:
    There is a reduction in the use of basic in vitro models for drug testing, with more research focusing on complex in vivo models that better mimic human physiology.

Similar Journals

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Transforming Ideas into Effective Therapeutics.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

JOURNAL OF MICROENCAPSULATION

Fostering Collaboration for Advancements in Microencapsulation
Publisher: TAYLOR & FRANCIS LTDISSN: 0265-2048Frequency: 8 issues/year

Welcome to the JOURNAL OF MICROENCAPSULATION, a leading academic publication devoted to the multifaceted applications and advancements in the fields of microencapsulation technology. Published by Taylor & Francis Ltd in the United Kingdom, this journal has been at the forefront of research since 1984, providing a platform for the dissemination of innovative studies encompassing bioengineering, organic chemistry, and pharmaceutical sciences, among other disciplines. With a commendable impact factor, the journal holds impressive rankings in its respective categories, including a Q2 status in Pharmaceutical Science and Physical and Theoretical Chemistry as of 2023. The JOURNAL OF MICROENCAPSULATION is committed to advancing knowledge through rigorous peer-reviewed articles, fostering collaboration among researchers, professionals, and students. While it operates under a traditional access model, it ensures that cutting-edge research reaches a broad readership, underscoring its significance in enhancing the understanding of microencapsulation processes and their applications across various industries.

Journal of Pharmaceutical Investigation

Elevating healthcare with cutting-edge pharmaceutical insights.
Publisher: SPRINGERNATUREISSN: 2093-5552Frequency: 6 issues/year

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS

Fostering Collaboration in Biomedical Engineering Excellence
Publisher: WILEYISSN: 1552-4973Frequency: 8 issues/year

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, published by Wiley, is a leading journal in the field of biomaterials and biomedical engineering, with an impact factor reflected in its relevant Scopus rankings—including a Q2 position in Biomedical Engineering and Q3 in Biomaterials for 2023. This journal, with ISSN 1552-4973 and E-ISSN 1552-4981, serves as a vital platform for disseminating pioneering research and innovative applications of biomaterials. Positioned in the United States, it aims to bridge the gap between material science and biological applications, fostering collaboration among researchers, professionals, and students dedicated to advancing technology in healthcare. With a convergence of studies from 2003 to 2024 and a growing focus on open access, the journal ensures greater visibility and accessibility for groundbreaking research. Join us in exploring the dynamic field of biomaterials, as we push the boundaries of science and engineering for improved patient outcomes.

Journal of Materials Chemistry B

Exploring Innovative Pathways in Materials Science.
Publisher: ROYAL SOC CHEMISTRYISSN: 2050-750XFrequency: 48 issues/year

Journal of Materials Chemistry B is a prestigious peer-reviewed journal published by the Royal Society of Chemistry, specializing in the latest advancements in the realm of materials chemistry. With a profound impact in the scientific community, this journal has achieved impressive Q1 quartile rankings in 2023 across several categories, including Biomedical Engineering, Miscellaneous Chemistry, Materials Science, and Medicine, illustrating its pivotal role in interdisciplinary research. Its impressive Scopus rankings further emphasize its widespread recognition, with notable placements in the top percentiles for various fields. Covering a broad scope of topics from novel materials for biomedical applications to innovative chemical synthesis techniques, the journal aims to promote knowledge exchange and foster collaborative research across disciplines. Although not an open-access journal, it offers a platform for researchers to share their findings and contribute to the evolving discourse within materials science. With a publication record spanning from 2013 to 2024, the Journal of Materials Chemistry B remains an essential resource for researchers, professionals, and students dedicated to exploring the frontiers of materials chemistry.

Advanced Healthcare Materials

Advancing the Frontiers of Biomedical Engineering
Publisher: WILEYISSN: 2192-2640Frequency: 12 issues/year

Advanced Healthcare Materials, published by WILEY, is a leading journal in the interdisciplinary fields of biomaterials, biomedical engineering, and pharmaceutical science. With its ISSN 2192-2640 and E-ISSN 2192-2659, the journal provides a platform for innovative research that encompasses the design, fabrication, and application of advanced materials in healthcare settings. Recognized for its high impact, it boasts a Q1 ranking in several categories, including a notable rank of #7/183 in Pharmaceutical Science and 14/137 in Biomaterials according to Scopus rankings. This reflects the journal’s commitment to publishing cutting-edge studies that push the boundaries of science and technology in medicine. Although it operates under a subscription model, articles published in this journal significantly impact the global research community and play a crucial role in the advancement of healthcare technologies. With a publication history from 2012 to 2024, Advanced Healthcare Materials remains an essential resource for researchers, professionals, and students engaged in the groundbreaking intersections of materials science and healthcare.

BIOMATERIALS

Advancing the Future of Biomaterials Research
Publisher: ELSEVIER SCI LTDISSN: 0142-9612Frequency: 36 issues/year

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.

ADVANCED DRUG DELIVERY REVIEWS

Unveiling the Future of Drug Delivery.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Materials Science & Engineering C-Materials for Biological Applications

Exploring groundbreaking materials for life-enhancing applications.
Publisher: ELSEVIERISSN: 0928-4931Frequency: 12 issues/year

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Journal of Reports in Pharmaceutical Sciences

Elevating Standards in Pharmaceutical Research and Education.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.